BioDelivery Sciences International (BDSI) Shares are Down -15.28%

BioDelivery Sciences International (BDSI) : During the past 4 weeks, traders have been relatively bearish on BioDelivery Sciences International (BDSI), hence the stock is down -4.11% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -14.72% relative to the S&P 500. The 4-week change in the price of the stock is -4.31% and the stock has fallen -15.28% in the past 1 week.

For the current week, the company shares have a recommendation consensus of Buy. The stock has recorded a twenty day Moving Average of 6.76% and the fifty day Moving Average is 2.51%. BioDelivery Sciences International, Inc. is up 15.64% in the last three month period. Year-to-Date the stock performance stands at -49.06%.

BioDelivery Sciences International (BDSI) : The highest level BioDelivery Sciences International (BDSI) is projected to reach is $13 for the short term and the lowest estimate is at $4. The consolidated price target from 7 rating analysts who initiate coverage on the stock is $7 and the possibility the share price can swing is $3.21.


BioDelivery Sciences International (NASDAQ:BDSI): On Fridays trading session , Opening price of the stock was $2.47 with an intraday high of $2.54. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $2.4. However, the stock managed to close at $2.44, a loss of 1.21% for the day. On the previous day, the stock had closed at $2.47. The total traded volume of the day was 639,738 shares.

BioDelivery Sciences International, Inc. is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction. The Companys products and certain of its product candidates utilize the BioErodible MucoAdhesive (BEMA) drug delivery technology, a small, erodible polymer film for application to the buccal mucosa (the lining inside the cheek). The Companys United Sates Food and Drug Administration (FDA) approved product, ONSOLIS (fentanyl buccal soluble film), as well as its approved product BUNAVAIL (buprenorphine and naloxone buccal film) and its product candidate, BELBUCA utilize its BEMA technology.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.